Science

Blog

Ozempic Side Effects

STUDY DEEP DIVE

The Ozempic Side Effect Nobody Warned You About: Your Gut Slows Down

A new Mayo Clinic study found high rates of bacterial and methanogen overgrowth in patients taking GLP-1 medications, raising important questions about motility, microbial balance, and gut health.

Study:
GLP-1 Receptor Agonist Use Is Associated With Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth

Authors:
Damianos JA, Fredrick TW, Jin MF, Ospina-Velasquez L, Wang XJ

Reviewed by:
Paula Owen & Andrea Helleman

Journal:
Foregut (2025)

Scientific Oversight:
Kenneth Brown, MD

Study Type:
Independent Study

VIEW STUDY

SYNOPSIS

GLP-1 Use Linked to Higher Rates of SIBO and IMO

This Mayo Clinic study examined 99 patients taking GLP-1 receptor agonists and found high rates of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO). The authors suggest that slower gastrointestinal motility may contribute to these findings by creating conditions that favor microbial overgrowth. Because most participants also had diabetes, the relationship remains associative rather than causal and warrants further study.

Key Takeaways

  • Researchers evaluated 99 patients taking GLP-1 receptor agonists and tested them for microbial overgrowth in the small intestine.
  • Among patients who underwent intestinal culture testing, 76.2% met the study's criteria for small intestinal bacterial overgrowth (SIBO).
  • Among patients who underwent breath testing, 30.6% tested positive for microbial overgrowth, with most positive results reflecting intestinal methanogen overgrowth (IMO).
  • The proposed mechanism is slowed gastrointestinal motility. When transit slows, microbes have more time to accumulate and ferment within the small intestine.
  • Because most participants also had diabetes, the study cannot determine whether the findings were driven by GLP-1 use, diabetes, or a combination of both.
  • The authors conclude that further research is needed to better understand the relationship between GLP-1 medications, intestinal transit, and microbial overgrowth.

WHY THIS CAUGHT OUR ATTENTION

Why This Matters Beyond GLP-1 Medications

What interests us about this study is not simply that it involves GLP-1 medications. It describes a gut environment that polyphenol researchers have been studying for years.

The authors observed bacterial overgrowth and intestinal methanogen overgrowth in a population taking medications known to slow gastrointestinal motility. While the study does not establish causation, it highlights an important pattern: when movement slows, the microbial environment of the small intestine can change.

At KBS, we are particularly interested in the relationship between motility, microbial balance, fermentation, and methane production. These mechanisms appear repeatedly across a wide range of digestive conditions, regardless of the original trigger.

This study does not tell us whether polyphenols are the answer. What it does do is help define the biological environment where future polyphenol research may be most relevant. For us, that makes it a study worth paying attention to.

WHAT IT MEANS FOR POLYPHENOL SCIENCE

The Connection Between Motility and Microbial Balance

The growing use of GLP-1 medications is creating a large population of people experiencing changes in gastrointestinal motility. Studies like this help researchers better understand what may happen downstream when transit slows and the microbial environment shifts.

For polyphenol researchers, that is particularly interesting because the findings touch on several interconnected mechanisms: motility, microbial balance, fermentation, and methane production. These patterns appear repeatedly across a range of digestive conditions and may play an important role in symptom development.

This study does not test polyphenols, nor does it suggest a treatment strategy. What it does provide is a clearer picture of the biological environment involved. Understanding how polyphenols interact with complex gut ecosystems remains an important area for future research.

As more research emerges, studies like this help identify where polyphenol science may have the greatest opportunity to contribute to our understanding of digestive health.

REFERENCE

  • Damianos JA, Fredrick TW, Jin MF, Ospina-Velasquez L, Wang XJ. GLP-1 receptor agonist use is associated with small intestinal bacterial overgrowth and intestinal methanogen overgrowth. Foregut. 2025. doi:10.1177/26345161251353437.
VIEW STUDY

This article is for educational purposes and summarizes published research. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Atrantil is a dietary supplement. Talk with your healthcare provider before changing any medication or supplement routine.